- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about BMY
Recent news which mentions BMY
Bristol Myers-2seventy Partnered Abecma Cuts Risk Of Disease Progression, Death By 51% In Pretreated Myeloma Patients
February 10, 2023
From Benzinga
2 Top Biotech Stocks to Buy Right Now
February 09, 2023
From Motley Fool
2 Top Biotech Stocks to Buy in February
February 08, 2023
From Motley Fool
Big Pharma Bristol-Myers Returns $475M IL-12 Oncology Asset To Dragonfly
February 06, 2023
Tickers
BMY
From Benzinga
Could This Indication Provide a Lift for Bristol Myers Squibb's Stock?
February 06, 2023
Tickers
BMY
From Motley Fool
1 Company Bucks the Office REIT Trend With Higher Rents and Earnings
February 06, 2023
From Motley Fool
What 5 Analyst Ratings Have To Say About Bristol-Myers Squibb
February 03, 2023
Tickers
BMY
From Benzinga
Bristol-Myers Squibb (BMY) Q4 2022 Earnings Call Transcript
February 02, 2023
Tickers
BMY
From Motley Fool
Revlimid Generic Competition Hurts Bristol Myers' Q4 Earnings, Issues Annual Outlook Within Expected Range
February 02, 2023
Tickers
BMY
From Benzinga
This trader nailed two big market calls in 2022. She says investors are ‘being paid to wait’ so should steer clear of stocks for 2023.
February 02, 2023
From MarketWatch
Nasdaq Futures Fly As Meta Keeps Tech Earnings' Buoyancy Intact: Will Apple, Amazon, Alphabet Toe In Line?
February 02, 2023
From Benzinga
Bristol-Myers Squibb Unusual Options Activity For February 01
February 01, 2023
Tickers
BMY
From Benzinga
Prothena Touts Encouraging Data From Early-Stage Alzheimer's Candidate
February 01, 2023
From Benzinga
Down 14.5%, Is Pfizer Stock a Screaming Buy?
January 30, 2023
From Motley Fool
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
January 29, 2023
From Benzinga
2 Top Dividend Stocks to Buy in 2023 and Hold Forever
January 29, 2023
From Motley Fool
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
January 27, 2023
From Motley Fool
3 Buffett-Type Stocks to Buy Right Now
January 25, 2023
From Motley Fool
5 Stocks You Can Confidently Invest $500 in Right Now
January 19, 2023
From Motley Fool
Neurodegenerative Diseases Focused Company Goes Public Via Wilbur Ross-Backed SPAC, Joins Alzheimer's Race To Compete Biogen
January 18, 2023
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 17, 2023
January 17, 2023
From Benzinga
Tickers
BMY
From Motley Fool
Drug companies plan to raise prices on vital medicines to fund R&D, but they already spend more on shareholder returns
January 13, 2023
From MarketWatch
7 Dividend-Paying Large-Cap Stocks to Buy in January
January 13, 2023
From InvestorPlace
From Motley Fool
Is Alexandria Real Estate Equity a Buy?
January 10, 2023
From Motley Fool
5 Top Pharma Stocks of 2022 to Buy for the Long Haul
January 06, 2023
From InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.